Complete Remission of Refractory, Ulcerated, Primary Cutaneous CD30+ Anaplastic Large Cell Lymphoma Following Brentuximab Vedotin Therapy

被引：10
|
作者：
Patsinakidis, Nikolaos [1 ]
Kreuter, Alexander [1 ]
Moritz, Rose K. C. [1 ]
Stuecker, Markus [1 ]
Moellenhoff, Katrin [1 ]
机构：
[1] Ruhr Univ Bochum, Dept Dermatol Venereol & Allergol, DE-44791 Bochum, Germany
来源：
ACTA DERMATO-VENEREOLOGICA | 2015年 / 95卷 / 02期
关键词：
LYMPHOPROLIFERATIVE DISORDERS; EORTC; ISCL;
D O I：
10.2340/00015555-1874
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
[No abstract available]
引用
收藏
页码：233 / 234
页数：2
相关论文
共 50 条
  • [41] Successful Therapy with Brentuximab Vedotin at clinic-adapted Delivery Intervals in primary cutaneous, CD30-positive, large-cell, anaplastic T-cell Lymphoma
    Bley, L. I.
    Schulze, H. J.
    Grundmann, S.
    Weishaupt, C.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 45 - 45
  • [42] Primary cutaneous CD 30+ anaplastic large cell lymphoma
    S. Devaji Rao
    R. Ravi
    Meera Govindarajan
    Indian Journal of Surgery, 2010, 72 : 283 - 285
  • [43] Primary cutaneous CD 30+anaplastic large cell lymphoma
    Rao, S. Devaji
    Ravi, R.
    Govindarajan, Meera
    INDIAN JOURNAL OF SURGERY, 2010, 72 : 283 - 285
  • [44] Complete remission of refractory disseminated NK/T cell lymphoma with brentuximab vedotin and bendamustine
    Li-Mei Poon
    Yok-Lam Kwong
    Annals of Hematology, 2016, 95 : 847 - 849
  • [45] Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma
    Illidge, Tim
    Bouabdallah, Reda
    Chen, Robert
    Gopal, Ajay K.
    Moskowitz, Craig H.
    Ramchandren, Radhakrishnan
    Shustov, Andrei R.
    Tilly, Herve
    Trippett, Tanya M.
    Gibb, Adam
    Grove, Laurie E.
    Advani, Ranjana
    LEUKEMIA & LYMPHOMA, 2015, 56 (03) : 703 - 710
  • [46] Cutaneous presentation on the eyelid of primary, systemic, CD30+, anaplastic lymphoma kinase (ALK)-negative, anaplastic large-cell lymphoma (ALCL)
    Mencia-Gutierrez, Enrique
    Gutierrez-Diaz, Esperanza
    Salamanca, Javier
    Martinez-Gonzalez, Miguel A.
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2006, 45 (06) : 766 - 769
  • [47] Combination therapy with brentuximab vedotin and cisplatin/cytarabine in a patient with primarily refractory anaplastic lymphoma kinase positive anaplastic large cell lymphoma
    Heidegger, Simon
    Beer, Ambros J.
    Geissinger, Eva
    Rosenwald, Andreas
    Peschel, Christian
    Ringshausen, Ingo
    Keller, Ulrich
    ONCOTARGETS AND THERAPY, 2014, 7 : 1123 - 1127
  • [48] Complete remission of refractory disseminated NK/T cell lymphoma with brentuximab vedotin and bendamustine
    Poon, Li-Mei
    Kwong, Yok-Lam
    ANNALS OF HEMATOLOGY, 2016, 95 (05) : 847 - 849
  • [49] A relapsed refractory CD30 positive cutaneous anaplastic large cell lymphoma with large B-cell transformation responding to brentuximab vedotin after multiple lines of treatment
    Erdem, S.
    Ozbalak, M.
    Baykal, C.
    Besisik, S. Kalayoglu
    LEUKEMIA RESEARCH, 2019, 85 : S60 - S60
  • [50] Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis
    Duvic, Madeleine
    Tetzlaff, Michael T.
    Gangar, Pamela
    Clos, Audra L.
    Sui, Dawen
    Talpur, Rakhshandra
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (32) : 3759 - +
12345